Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


Cancer-fighting cocktail demonstrates promising results as new treatment for advanced cervical cancer
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

Cheaper alternative to licensed drug for treating eye disease has similar side-effects
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

Women & Infants Breast Cancer Specialist Reports Advance in Treatment of Triple-Negative Breast Cancer
William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women.

Hijacking the brain's blood supply: Tumor discovery could aid treatment
Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Researcher discovers ovarian cancer treatment
Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

Clinical trial shows drug combination may be effective in recurrent ovarian cancer
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today.

Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Major Advances in Breast, Prostate and Colorectal Cancer Treatment Featured at ASCO's Annual Meeting
Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO).
More Bevacizumab Current Events and Bevacizumab News Articles

Tarascon Pocket Oncologica

Tarascon Pocket Oncologica
by Mark A. Marinella (Author)


The Tarascon Pocket Oncologica is a concise, organized pocket resource covering the diagnosis and treatment of over 30 of the most common types of cancer. Each section includes background information for each type of cancer as well as the pathobiology, clinical presentation, physical findings, recommended diagnostic tests, staging, treatment options, potential complications of treatment, follow up care, prognosis and a list of additional references. Numerous tables allow for quick and easy retrieval of information. The Tarascon Pocket Oncologica is the perfect portable reference for the busy oncologist, primary care physicians and residents caring for patients with cancer.

Clinical Gynecologic Oncology: Expert Consult - Online and Print, 8e

Clinical Gynecologic Oncology: Expert Consult - Online and Print, 8e
by Philip J. DiSaia MD (Author), William T. Creasman MD (Author)


Clinical Gynecologic Oncology, by Drs. Di Saia and Creasman, is the leading medical reference book geared toward helping you improve gynecologic cancer outcomes. You'll see how to take advantage of the latest advances in early detection and improved treatment options for gynecologic cancers, especially uterine and cervical cancers, equipping you with the skills you need to provide effective and compassionate care for your patients.Easily identify and absorb key information with outlines beginning each chapter. Choose the best management plan for each patient using algorithms throughout the book. Stay at the forefront of your field thanks to new chapters on Genetic Counseling and Clinical Management of Inherited Disease; Molecular Genetics; and Minimally Invasive Surgery, plus sweeping...

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

  Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article): An article from: Family Practice News
by Jeff Evans (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2003. The length of the article is 1131 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article)
Author: Jeff Evans
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2003
Publisher: International Medical News Group
Volume: 33 Issue: 17 Page: 42(1)

Article Type: Brief Article

Distributed by Thomson...

  Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds): An article from: Internal Medicine News
by Jeff Evans (Author)


This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 318 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds)
Author: Jeff Evans
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 19 Page: 26(1)

Distributed by Thomson...

  Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology): An article from: Internal Medicine News
by International Medical News Group (Publisher)


This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2005. The length of the article is 530 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology)
Publication: Internal Medicine News (Magazine/Journal)
Date: April 1, 2005
Publisher: International Medical News Group
Volume: 38 Issue: 7 Page: 69(1)

Distributed by Thomson...

  Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on June 15, 2005. The length of the article is 1884 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: June 15, 2005
Publisher: International Medical News Group
Volume: 35 Issue: 12 Page: 1(2)

Distributed by Thomson...

  Bevacizumab improved survival in leading cancers.(Clinical Rounds): An article from: Skin & Allergy News
by Jane Salodof MacNeil (Author)


This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2005. The length of the article is 1396 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improved survival in leading cancers.(Clinical Rounds)
Author: Jane Salodof MacNeil
Publication: Skin & Allergy News (Magazine/Journal)
Date: July 1, 2005
Publisher: International Medical News Group
Volume: 36 Issue: 7 Page: 60(1)

Distributed by Thomson...

  Bevacizumab aids survival in cancer.(News): An article from: Internal Medicine News
by Jane Salodof MacNeil (Author)


This digital document is an article from Internal Medicine News, published by Thomson Gale on June 15, 2005. The length of the article is 1903 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in cancer.(News)
Author: Jane Salodof MacNeil
Publication: Internal Medicine News (Magazine/Journal)
Date: June 15, 2005
Publisher: Thomson Gale
Volume: 38 Issue: 12 Page: 1(3)

Distributed by Thomson...

  Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by Thomson Gale on September 1, 2006. The length of the article is 713 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 36 Issue: 17 Page: 43(1)

Distributed by Thomson...

© 2014 BrightSurf.com